Pharma: Page
-
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study
The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19.
By Ben Fidler • Updated Oct. 27, 2020 -
Getty Images
Sponsored by SAPRegulatory-driven material control with SAP
Learn about material segmentation, a unique approach for characteristics-based planning and execution.
By Stephen Cloughley, Senior Director, SAP Life Sciences IBU • Oct. 26, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Purdue, reaching $8B settlement with US, pleads guilty to charges over opioid sales
Under a deal reached with the Department of Justice, Purdue faces fines and a forfeiture worth more than $5 billion — the largest penalties ever for a drug company.
By Jacob Bell • Oct. 21, 2020 -
Sponsored by ZS
Patients and physicians brace for flu season amid COVID-19
ZS surveyed more than 500 patients and 500 physicians to gather their perspectives on COVID-19's potential impact on flu vaccination rates.
Oct. 21, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
J&J halts studies of coronavirus vaccine due to participant's illness
The company did not disclose details, nor could it confirm whether the participant had received its shot. But J&J is now the second vaccine developer, along with AstraZeneca, to suspend testing for a safety review.
By Ned Pagliarulo • Updated Oct. 13, 2020 -
Getty Images
Mallinckrodt, beset by opioid drug suits, files for bankruptcy
The drugmaker aims to resolve billions of dollars in opioid-related claims and a federal lawsuit over Medicaid rebates, liabilities it says would be "otherwise unmanageable."
By Ned Pagliarulo • Oct. 12, 2020 -
Ewa Krawczyk, National Cancer Institute
Pfizer stumbles again in early breast cancer study, clearing path for Eli Lilly
The latest setback for Pfizer's top-selling Ibrance leaves Lilly's Verzenio, for now, as the only drug in its class to be proven to stave off breast cancer recurrence after surgery.
By Ben Fidler • Oct. 9, 2020 -
Merck research chief Roger Perlmutter to retire, leaving immunotherapy legacy
Under his leadership, Merck developed a once overlooked cancer drug into Keytruda, now a top-selling medicine and foundational treatment for more than a dozen types of tumors.
By Ned Pagliarulo • Oct. 2, 2020 -
AstraZeneca restarts another coronavirus vaccine trial, but US delay lingers
The company is now cleared to resume testing of its experimental shot in multiple countries, but a Phase 3 trial in the U.S. remains halted as an FDA investigation reportedly widens.
By Ben Fidler • Oct. 2, 2020 -
Pfizer pushes deeper into China with stake in cancer biotech
The $200 million investment in CStone Pharmaceuticals puts Pfizer in charge of selling a cancer immunotherapy in the world's second largest drug market.
By Jacob Bell • Sept. 30, 2020 -
Ironwood lays off one-third of staff after heartburn drug falls short in study
The company will halt further work on its only fully owned drug and focus instead on expanding sales of its marketed product Linzess.
By Jonathan Gardner • Updated Sept. 29, 2020 -
Boghosian, Joyce. (2020). "President Trump meets with the Coronavirus Task Force" [Photograph]. Retrieved from Flickr.
Trump forges ahead with drug import plan, but impact in doubt
Under the proposed plan, states would be permitted to import lower-priced products from Canada and drugmakers from around the globe. But participation is uncertain, as is the plan's effect on drug prices.
By Jonathan Gardner • Sept. 25, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
J&J begins largest Phase 3 study of a coronavirus vaccine
The trial, which launched Wednesday in the U.S., South Africa and several South American countries, will enroll as many as 60,000 participants.
By Ned Pagliarulo • Sept. 23, 2020 -
Permission granted by Novartis
FDA sets back Novartis plans to expand use of SMA gene therapy
The agency has asked the company to run a new study of the Zolgensma formulation that it aims to bring to older patients with spinal muscular atrophy.
By Ben Fidler • Sept. 23, 2020 -
FDA decision on Bristol Myers cell therapy could come down to the wire
An FDA decision on Bristol Myers' myeloma treatment ide-cel could come four days before a key deadline related to the pharma's buyout of Celgene.
By Jonathan Gardner • Sept. 22, 2020 -
Ewa Krawczyk, National Cancer Institute
With Eli Lilly data, another drug emerges to stop breast cancers from returning
The highly anticipated results could change how some patients with the most common form of breast cancer are treated — and drive up the costs of care.
By Ben Fidler • Sept. 20, 2020 -
Kendall Davis/BioPharma Dive
Arrowhead shares soar on liver disease data from four patients
Encouraged by the early study results, Arrowhead plans to ask regulators to streamline its clinical trials, which could pressure rivals Vertex and Dicerna.
By Jonathan Gardner • Sept. 16, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
Lilly offers first evidence that its antibody drug may help treat COVID-19
The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear.
By Ben Fidler • Sept. 16, 2020 -
Courtesy of Novavax, Australian Broadcasting Corporation
Novavax boosts coronavirus vaccine manufacturing capacity as key trial nears
The Serum Institute of India, a go-to partner for coronavirus vaccine makers, will help Novavax boost capacity to levels matching its larger rivals.
By Jonathan Gardner • Sept. 15, 2020 -
AstraZeneca, Oxford vaccine study allowed to restart in UK
Six days after a worrisome illness in a U.K. study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume.
By Ben Fidler • Sept. 12, 2020 -
GSK inhaler locks down a coveted approval in asthma
The approval helps differentiate Trelegy Ellipta, a three-drug treatment for COPD and, now, asthma, in the crowded respiratory drug market.
By Jacob Bell • Sept. 10, 2020 -
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
With BioMarin's gene therapy sidelined, attention is turning to other drugs, including one Sanofi acquired when it paid $11.6 billion for Bioverativ.
By Jacob Bell • Sept. 10, 2020 -
Getty Images
Sponsored by ZSThe voice of the customer, and how pharma can respond
ZS surveyed more than 500 physicians, 500 patients and 30 healthcare administrators to gather their current thoughts on care delivery, telemedicine and pharma's potential role during the COVID-19 pandemic.
By Yasasvi Popuri, Jay Lichtenstein & Ganesh Vedarajan • Sept. 10, 2020 -
Jacob Bell/BioPharma Dive
Merck takes aim at Pfizer with pneumonia vaccine data
Results from two Phase 3 studies put Merck in position to ask for FDA approval of its shot later this year. Pfizer may not be far behind with a rival product.
By Jonathan Gardner • Sept. 9, 2020 -
Danielle Ternes/BioPharma Dive
Deep DiveHow biotech and pharma companies pay their CEOs, and their workers
The median CEO of 231 drug companies analyzed by BioPharma Dive earned 50% more last year than in 2017, a leap that far outpaced the more modest pay gains among employees.
By Ned Pagliarulo • Sept. 9, 2020
Previous
